KL (Klotho)

In conclusion, low Klotho-high LRP6 expression was associated with poor OS, supporting its role as a prognostic biomarker and potential therapeutic target. Validation in larger patient cohorts is warranted to confirm their clinical utility.

These findings suggest that LKB1 loss suppresses DPP4 expression, contributing to the immunosuppressive characteristics of the TME in KL-NSCLC cells, whereas restoring DPP4 expression promotes NK cell recruitment, facilitates immune activation, and enhances the effects of anti-PD-1 therapy. These results suggest that DPP4 is a key immune modulator and a promising therapeutic target, providing a novel strategy to overcome immune resistance and improve immunotherapy outcomes in this challenging subset of lung cancer.

Mild moxibustion exerts anti-aging effects on the thoracic aorta and kidney of senescent rats, which may be related with its effect on modulating the miR-34a/sirt1/p53 signaling pathway.

These findings suggest a dichotomous role for KL and FGF23 in ccRCC, with KL functioning as a favorable prognostic factor and FGF23 potentially contributing to disease progression and early relapse. Further mechanistic studies are warranted to elucidate their interplay and evaluate their utility as biomarkers or therapeutic targets in renal cancer.

Klotho protein affects the expression of GH and IGF-1 in JEG-3 cells, leading to the dysfunction of GH/IGF-1 axis, which subsequently impacts the proliferation, migration, anti-inflammatory response, and glucose metabolism of placental trophoblast cells, ultimately affecting placental function and fetal intrauterine development.

Compared to MSCs, s-KL MSCs also exhibited an enhanced capacity for differentiation and maturation of oligodendrocytes, as demonstrated by increased mRNA and protein expression of Olig2 and Nogo-A in the CNS of mice with EAE. These findings indicate that overexpression of s-KL enhances the therapeutic potential of MSCs to induce remyelination and may represent a novel approach to improve the efficacy of stem cell-based therapy in MS.

Correlation analyses across tumor stages indicate dynamic shifts, with tumor suppressors maintaining positive associations with ferroptosis markers and anti-aging/circadian markers showing stage-dependent changes. Despite the inherent limitations of our study, these findings highlight the evolving biomarker landscape in CRC progression, although further research is needed to elucidate their clinical implications.

We confirmed the presence of FN1-FGFR1 fusion genes and Klotho expression in most PMTs (6 out of 8). specific SNARE proteins gene upregulation along with transcriptional signatures of PMT offer new insights into its pathogenesis which may be further studied for diagnostic and therapeutic interventions.

Understanding these pathways offers promising avenues for therapeutic interventions to extend health span and lifespan. Targeting mechanisms such as telomerase activation, Klotho supplementation, ACE inhibition, and NF-κB modulation hold potential for combating the detrimental effects of aging and promoting healthier aging in the population.

Given its expression in human M1-like GAMs, serum KL levels can offer valuable insights into the immune microenvironment and hold clinical significance as a peripheral biomarker. These findings highlight the pivotal role of Klotho as a prognostic biomarker for predicting responses to immunotherapy, with potential applications for monitoring tumor progression or regression through changes in serum levels.

This study contributes a novel finding of serum Klotho protein in BC pathogenesis and explores its utility as a blood-based biomarker.

Tempol is a promising agent against sepsis-induced organ damage. This was evident in its cardiorenal protective effect, up-regulation of klotho, suppression of inflammation, oxidation, and apoptosis, and enhancement of the antioxidant status.